What is Flatiron?
Founded in 2012 and headquartered in New York City, Flatiron operates at the intersection of oncology and big data. The company provides a comprehensive software platform that aggregates real-world clinical data to improve patient outcomes and streamline research processes. By bridging the gap between clinical practice and research, Flatiron enables healthcare providers and pharmaceutical companies to make data-driven decisions in the fight against cancer. Its market position is defined by its ability to transform fragmented health records into actionable insights, effectively serving as a critical infrastructure layer for modern oncology.
How much funding has Flatiron raised?
Flatiron has raised a total of $313M across 3 funding rounds:
Series A
$8M
Series B
$130M
Series C
$175M
Series A (2012): $8M with participation from Laboratory Corporation of America, Lerer Ventures, BoxGroup, Great Oaks Venture Capital, SV Angel, The Social+Capital Partnership, Google Ventures, and First Round Capital
Series B (2014): $130M led by Laboratory Corporation of Americau00ae Holdings, Google Ventures, and First Round Capital
Series C (2016): $175M supported by Allen & Company LLC, First Round Capital, Casdin Capital, LLC, Google Ventures, Roche, and Baillie Gifford
Key Investors in Flatiron
Google Ventures
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, and frontier technology innovations.
Laboratory Corporation of America
Labcorp Holdings Inc. operates as a laboratory services company that provides vital diagnostic information to help doctors, hospitals, and researchers make confident clinical decisions.
First Round Capital
First Round Capital is a venture capital firm that invests in innovative startups across various sectors, focusing on supporting entrepreneurs to achieve significant market results.
What's next for Flatiron?
With the backing of major institutional investors, Flatiron is well-positioned to scale its enterprise-level operations. The current lifecycle stage suggests a focus on deepening its diagnostic capabilities and expanding its footprint within the global pharmaceutical research ecosystem. Future strategic initiatives will likely prioritize the integration of personalized medicine workflows and the enhancement of its proprietary data analytics engine to maintain its competitive edge in the life sciences market.
See full Flatiron company page
